BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 29972828)

  • 1. Reducing Fibrinogen and Factor XIII Using Double-Filtration Plasmapheresis for Antibody-Mediated Rejection: Predictive Models.
    Jouve T; Marlu R; Malvezzi P; Seyve L; Maurizi J; Carron PL; Polack B; Rostaing L
    Blood Purif; 2018; 46(3):239-245. PubMed ID: 29972828
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of double-filtration plasmapheresis for antibody-mediated rejection on hemostasis parameters and thrombin generation.
    Marlu R; Malvezzi P; Seyve L; Jouve T; Maurizi J; Defendi F; Carron PL; Christophe M; Le Gouellec A; Polack B; Rostaing L
    Thromb Res; 2018 Jun; 166():113-121. PubMed ID: 29747114
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of Biopsy-Proven Acute Antibody-Mediated Rejection Using Thymoglobulin (ATG) Monotherapy and a Combination of Rituximab, Intravenous Immunoglobulin, and Plasmapheresis: Lesson Learned from Primary Experience.
    Zheng J; Xue W; Qing X; Jing X; Hou J; Tian X; Guo Q; He X; Cai J
    Clin Transpl; 2014; ():223-30. PubMed ID: 26281149
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Double filtration plasmapheresis can decrease factor XIII Activity.
    Hanafusa N; Kondo Y; Suzuki M; Nakao A; Noiri E; Fujita T
    Ther Apher Dial; 2007 Jun; 11(3):165-70. PubMed ID: 17497996
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of antibody-mediated rejection with double-filtration plasmapheresis, low dose IVIg plus rituximab after kidney transplantation.
    Naciri Bennani H; Daligault M; Noble J; Bardy B; Motte L; Giovannini D; Emprou C; Fiard G; Imerzoukene F; Bourdin A; Masson D; Janbon B; Malvezzi P; Rostaing L; Jouve T
    J Clin Apher; 2021 Aug; 36(4):584-594. PubMed ID: 33783868
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective plasma exchange can reduce auto-antibodies in patients with bullous pemphigoid without affecting factor XIII and fibrinogen.
    Nasu K; Hanafusa N; Nangaku M
    J Clin Apher; 2017 Dec; 32(6):589-591. PubMed ID: 27709645
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Virus removal and eradication by modified double filtration plasmapheresis decreases factor XIII levels.
    Hanafusa N; Satonaka H; Doi K; Noiri E; Fujita T
    Ther Apher Dial; 2010 Jun; 14(3):287-91. PubMed ID: 20609180
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Significance of low-level DSA detected by solid-phase assay in association with acute and chronic antibody-mediated rejection.
    Hirai T; Kohei N; Omoto K; Ishida H; Tanabe K
    Transpl Int; 2012 Sep; 25(9):925-34. PubMed ID: 22764746
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of different apheresis modalities on coagulation factor XIII level during antibody removal in ABO-blood type incompatible living related renal transplantation.
    Hanafusa N; Hamasaki Y; Kawarasaki H; Kido R; Shibagaki Y; Ishikawa A; Enomoto Y; Fujita T; Noiri E; Nangaku M
    Transfus Apher Sci; 2013 Oct; 49(2):254-8. PubMed ID: 23827327
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of therapeutic plasma exchange and double filtration plasmapheresis on hemostasis in renal transplant recipients.
    Vatazin AV; Zulkarnaev AB
    Ter Arkh; 2018 Jun; 90(6):22-27. PubMed ID: 30701900
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Indicators of treatment responsiveness to rituximab and plasmapheresis in antibody-mediated rejection after kidney transplantation.
    Immenschuh S; Zilian E; Dämmrich ME; Schwarz A; Gwinner W; Becker JU; Blume CA
    Transplantation; 2015 Jan; 99(1):56-62. PubMed ID: 25121474
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Frequent development of subclinical chronic antibody-mediated rejection within 1 year after renal transplantation with pre-transplant positive donor-specific antibodies and negative CDC crossmatches.
    Yamanaga S; Watarai Y; Yamamoto T; Tsujita M; Hiramitsu T; Nanmoku K; Goto N; Takeda A; Morozumi K; Katayama A; Saji H; Uchida K; Kobayashi T
    Hum Immunol; 2013 Sep; 74(9):1111-8. PubMed ID: 23792054
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Decreased factor XIII activity in a patient with subcutaneous bleeding after double filtration plasmapheresis.
    Seishima M; Shibuya Y; Kato G; Aoki T
    Ther Apher Dial; 2009 Jun; 13(3):229-31. PubMed ID: 19527471
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-tolerability of double-filtration plasmapheresis in antibody-incompatible kidney transplant candidates.
    Hebibi H; Weclawiak H; Rostaing L; Beaudreuil S; Allal A; François H; Durrbach A; Kamar N
    Saudi J Kidney Dis Transpl; 2015 Mar; 26(2):297-301. PubMed ID: 25758878
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of alloantibody strength in crossmatch negative DSA positive kidney transplantation.
    Wu P; Jin J; Everly MJ; Lin C; Terasaki PI; Chen J
    Clin Biochem; 2013 Oct; 46(15):1389-93. PubMed ID: 23726814
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intensive plasmapheresis and intravenous immunoglobulin for treatment of antibody-mediated rejection after kidney transplant.
    Ruangkanchanasetr P; Satirapoj B; Termmathurapoj S; Namkhanisorn K; Suaywan K; Nimkietkajorn V; Luesutthiviboon L
    Exp Clin Transplant; 2014 Aug; 12(4):328-33. PubMed ID: 25095710
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Isoagglutinin removal by plasma centrifugation or filtration (single or double): A prospective study in a single center.
    Naciri Bennani H; Noble J; Chevallier E; Terrec F; Motte L; Giroux-Lathuile C; Bugnazet M; Imerzoukene F; Janbon B; Malvezzi P; Rostaing L; Jouve T
    J Clin Apher; 2021 Feb; 36(1):149-160. PubMed ID: 33230824
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of three modalities of plasmapheresis on coagulation: Centrifugal, single-membrane filtration, and double-filtration plasmapheresis.
    Marlu R; Naciri Bennani H; Seyve L; Noble J; Chevallier E; Motte L; Imerzoukene F; Bugnazet M; Christophe M; Malvezzi P; Jouve T; Rostaing L
    J Clin Apher; 2021 Jun; 36(3):408-419. PubMed ID: 33506958
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of immunoadsorption to reduce donor-specific alloantibodies in kidney-transplant candidates.
    Rostaing L; Congy N; Aarnink A; Maggioni S; Allal A; Sallusto F; Game X; Kamar N
    Exp Clin Transplant; 2015 Apr; 13 Suppl 1():201-6. PubMed ID: 25894155
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Double filtration plasmapheresis in antibody-incompatible kidney transplantation.
    Higgins R; Lowe D; Hathaway M; Lam FT; Kashi H; Tan LC; Imray C; Fletcher S; Chen K; Krishnan N; Hamer R; Zehnder D; Briggs D
    Ther Apher Dial; 2010 Aug; 14(4):392-9. PubMed ID: 20649760
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.